Elsevier

Neuroscience Letters

Volume 85, Issue 3, 10 March 1988, Pages 291-296
Neuroscience Letters

Dextromethorphan protects against cerebral infarction in a rat model of hypoxia-ischemia

https://doi.org/10.1016/0304-3940(88)90581-2Get rights and content

Abstract

We assessed the cerebral protective effects of the noncompetitive N-methyl-d-aspartate antagonist dextromethorphan (DM; 10–35 mg/kg i.p.) in 8-day-old rats that were subjected to brain hypoxia-ischemia by tying one carotid artery and placing them in 8% O2 92% N2 for 2 h. Light microscopic examination of brains perfused one week after the insult revealed that all control animals developed a frank infarction with cavitation and brain shrinkage in the middle cerebral artery territory. There was a highly significant decrease in the incidence of frank infarction in DM-pre-treated pups vs saline-treated littermates, although there was no clear relationship between drug dose and the degree of brain protection. DM and its active metabolite dextrorphan may prove to be clinically useful in protecting against hypoxia-ischemia.

References (21)

There are more references available in the full text version of this article.

Cited by (84)

  • The common antitussive agent dextromethorphan protects against hyperoxia-induced cell death in established in vivo and in vitro models of neonatal brain injury

    2014, Neuroscience
    Citation Excerpt :

    As relative hyperoxia cannot be prevented and therapeutic use of oxygen is often necessary in the clinical setting, the pre-clinical evaluation of substances with the potential to counteract detrimental oxygen effects is of utmost importance. DM is a common antitussive agent with multiple mechanisms of action and known anti-oxidative properties that has already proven its neuroprotective potential in several animal models of neonatal brain injury (Prince and Feeser, 1988; Laroia et al., 1997; Keller et al., 2008). To the best of our knowledge we are the first to show beneficial effects of DM in both in vitro and in vivo models of hyperoxia-induced injury in the developing brain, while ruling out a major negative impact on healthy brain tissue.

  • Neuroprotective effects of hibernation-regulating substances against low-temperature-induced cell death in cultured hamster hippocampal neurons

    2006, Brain Research
    Citation Excerpt :

    ADO acts as a neuromodulator in the CNS and the neuroprotective effect of ADO against ischemic or traumatic neuronal injury has been well documented experimentally (Gidday et al., 1995; Schubert et al., 1997; Sweeney, 1997; von Lubitz and Marangos, 1990). Moreover, opioid receptor agonists elicit neuroprotective effects against neurodegeneration induced by ischemia and trauma (Chen et al., 2005; Lyeth et al., 1995; Prince and Feeser, 1988). In this study, we investigated if hibernation-regulating substances (HRS) such as ADO, opioids and TRH would protect hippocampal cultures from low-temperature-induced neuronal cell death (LTCD).

  • Dextromethorphan attenuates morphine withdrawal syndrome in neonatal rats passively exposed to morphine

    2002, European Journal of Pharmacology
    Citation Excerpt :

    This potency of dextromethorphan is generally close to that in suppressing morphine withdrawal syndrome in adult rats reported by others (Farzin, 1999; Mao et al., 1996). It is also within the potency range for attenuating other neuropathologies related to overactivation of the NMDA receptor in neonatal rats (Laroia et al., 1997; Prince and Feeser, 1988). In addition, the potency of MK-801 seems to be at least 40-fold higher than that of dextromethorphan, since postnatal injection of 0.5 mg/kg MK801 was as effective as that of 20 mg/kg of dextromethorphan, and prenatal co-injection of 0.1 mg/kg MK-801 was as effective as that of 10 mg/kg of dextromethorphan.

View all citing articles on Scopus
View full text